Navigation Links
ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
Date:9/4/2012

BARCELONA, Spain, September 4, 2012 /PRNewswire/ --

  • E-52862 is a potent, highly selective NCE with a novel mechanism of action (MOA; Sigma 1 Receptor (S1R) antagonism) currently being evaluated for the treatment of pain
  • Key data are outlined from three Phase I studies involving 175 male and female human subjects
  • These studies demonstrate a favourable safety, tolerability, pharmacokinetic and pharmacodynamic profile for E-52862
  • Phase II clinical trials evaluating E-52862 are ongoing

ESTEVE announces the recent publication of data from the Phase I clinical trial programme of a novel, highly potent and selective, once-daily, S1RA E-52862, developed by the ESTEVE R&D team, in the British Journal of Clinical Pharmacology[1].

     (Logo: http://photos.prnewswire.com/prnh/20120904/554843)

Mariano Sust, M.D., corresponding author, stated that "E-52862 represents a NCE with a novel, unprecedented mechanism of action for pain of different aetiologies.  We are very encouraged by these results and look forward to future findings from the E-52862 clinical trial programme in due course."

To fully validate the safety and tolerability of E-52862, ESTEVE performed a rigorous phase I programme. This publication reports results from three, Phase I studies involving 175 human subjects. E-52862 demonstrated a favourable safety and tolerability profile across a robust panel of assessments including adverse event recording following questioning and spontaneous reporting; physical examinations; vital signs measurements; laboratory safety tests (haematology, blood coagulation, biochemistry, urinalysis); multiple psychometric tests; computerized cognitive evaluations (including assessment of executive function, working memory and learning, reaction time and psychomotor functions); and thorough cardiac monitoring
'/>"/>

SOURCE ESTEVE
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ESTEVE Communicates its R&D Through a New Interactive Platform
2. Texas Medical Center, the largest concentration of medical research, educational and healthcare organizations in the world, announces the first Houston Stem Cell Summit to highlight the latest stem cell research and commercialization efforts
3. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
4. ARMGO Pharma, Inc. announces data which supports its Rycal program as a novel approach for the treatment of stress-induced cognitive disorders
5. Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Companys Long-Acting IL-11 Analog to Prevent Renal Ischemia Reperfusion Injury
6. Clinical Site Services, Industry Leader in Patient Enrollment Solutions, Announces New Website
7. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
8. Pinnaclife, Inc., Announces NDC, Inc., to Exclusively Distribute the New Animal Health Product Line!
9. Elsevier / Gold Standard Announces New Drug Class Overviews for Clinical Pharmacology
10. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
11. UBM Announces Partnership Agreement With Trade Organisation - SIPPO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... 2014 Research and Markets  has announced ... Analyzer, and Gas Chromatograph Market by Type , Technology, ... Trends & Forecast to 2013 - 2020" report ... is a process analytical instrument that provides chemical composition ... the way by which companies carry out their production ...
(Date:9/29/2014)... , Sept. 29, 2014 Burnham Securities ... Channel Group ("TCG"), a leader in healthcare venture ... formed an alliance to expand the range of ... With the alliance, Burnham Securities will be supported ... clinical medicine and management in healthcare industry to ...
(Date:9/29/2014)... , September 29, 2014 Atox ... severe infections, today announced that the Biomedical Advanced Research ... Bio with a contract valued up to $24 million ... treat Necrotizing Soft Tissue Infections (NSTI) and potentially infections ... in sepsis. BARDA awarded the contract to ...
(Date:9/29/2014)... Westbridge Agricultural Products announced today the ... effective new tool for organic growers. SUPPRESS™ Herbicide ... herbicide for post-emergent, non-selective weed control for use ... formulation is an emulsifiable concentrate that has been ... for use in organic food production. , In ...
Breaking Biology Technology:Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 3Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority (BARDA) 2Westbridge Receives EPA Approval for Its New SUPPRESS™ Herbicide EC 2
... Calif., Sept. 29, 2011 Ambry Genetics today ... provide CLIA-approved exome services for applications in clinical ... geneticists and medical directors, these results will allow ... have eluded traditional diagnostic approaches. ...
... 29, 2011 Dr. Barrett Bready, CEO of NABsys, ... Year. Dr. Bready will be honored at a ceremony ... presented by the Providence Business News in partnership with ... Bryant University, Cox Business, Edwards Angell Palmer & Dodge, ...
... system, you probably think about it fighting off a cold. ... immune cells in your brain may contribute to how you ... 10,000 years of using alcohol, and several decades of investigation ... our brain, we are still trying to figure out exactly ...
Cached Biology Technology:Ambry Genetics First to Offer Exome Sequencing Service for Clinical Diagnostics. 2NABsys CEO Barrett Bready Named Rhode Island Innovator of the Year 2Alcohol-related behavior changes -- blame your immune system 2
(Date:9/29/2014)... from the skeleton of a man who lived 2,330 years ... ourselves as humans? A great deal when his DNA profile ... terms found to-date in a region where modern humans ... , The man,s maternal DNA, or ,mitochondrial DNA, was sequenced ... Mitochondrial DNA provided the first evidence that we all come ...
(Date:9/29/2014)... -- NXT-ID, Inc. (Nasdaq: NXTD and ... focused on the growing mobile commerce market, today announced ... the Company,s Vice-President and Chief Financial Officer effective immediately. ... Financial Officer. Mr. Pereira will continue to serve as ... Mr. Miceli, age 56, has extensive hands ...
(Date:9/29/2014)... were able to safely tolerate treatment with cells cultured ... today in the journal Multiple Sclerosis and Related ... its kind, was conducted by researchers at Mount Sinai, ... at several other institutions. , While designed to ... data also suggested that a preparation of cultured cells ...
Breaking Biology News(10 mins):Ancient human genome from southern Africa throws light on our origins 2Ancient human genome from southern Africa throws light on our origins 3NXT-ID, Inc. Names Vice-President and Chief Financial Officer 2NXT-ID, Inc. Names Vice-President and Chief Financial Officer 3Cells from placentas safe for patients with multiple sclerosis 2
... A team led by the University of Colorado Boulder has been ... Energy to research modifying E. coli to produce biofuels ... take what we have worked on for the past decade to ... CU-Boulder,s Renewable and Sustainable Energy Institute, or RASEI. "In this project, ...
... Ian Bell, PhD, the Louis Block Distinguished Service Professor ... the Kovler Diabetes Center at the University of Chicago, ... 2012 for his pioneering work in understanding the role ... The prize, the world,s largest award for ...
... scientists produce better climate-resistant corn and other food production plants ... what we eat. Kansas State University geneticists and colleagues ... and prioritize the genes in humans, it improved the likelihood ... control quantitate traits in plants, such as how the plants ...
Cached Biology News:CU-led team receives $9.2 million DOE grant to engineer E. coli into biofuels 2University of Chicago's Graeme Bell receives international diabetes prize 2University of Chicago's Graeme Bell receives international diabetes prize 3Study finds prioritizing rather than canvassing entire plant genome may lead to improved crops 2Study finds prioritizing rather than canvassing entire plant genome may lead to improved crops 3
High affinity antibody reacting with S-100 ab heterodimer. Could be used for Western blotting application and immunoassay....
... Ingredients (g/L):,Tryptone, 10 ,Yeast extract, ... ,S-Gal, 0.3 ,Ferric ammonium citrate, 0.5 ... patented, water soluble, autoclavable chromogenic substrate ... S-Gal by -galactosidase generates a black ...
S-100 alpha/beta chain (8B10)...
SCCRO (S-17)...
Biology Products: